11Apr 2025
Nano-Based COVID-19 Vaccine Shows Safety and Strong T Cell Response in Early Trial

Nano-Based COVID-19 Vaccine Shows Safety and Strong T Cell Response in Early Trial

The PepGNP-Covid19 vaccine, a gold nanoparticle-based T cell vaccine, proved safe and immunogenic in a phase 1 trial. No serious adverse events were reported, and strong CD8+ T cell responses were seen, especially in memory subsets. This promising vaccine approach may offer broader, long-lasting protection against SARS-CoV-2 and reduce immune escape risks.

  • #general medicine
  • #pulmonology

Like

Save

Share